Last updated: 04/01/2021 10:10:05

PRJ2311: Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry

GSK study ID
200990
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Recruitment complete
Recruitment complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: PRJ2311: Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry
Trial description: Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase after the introduction of liraglutide, exenatide once-weekly, albiglutide, and other GLP-1 receptor agonists into the US market.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Annual incidence of MTC in the US to identify any possible increase after the introduction of liraglutide, exenatide once-weekly, albiglutide and other GLP-1 receptor agonists into the US market

Timeframe: 15 years

Secondary outcomes:
Not applicable
Interventions:
  • Other: No treatment given
    • Enrollment:
    1
    Primary completion date:
    2029-31-12
    Observational study model:
    Case-Only
    Time perspective:
    Prospective
    Clinical publications:
    Not applicable
    Medical condition
    Diabetes Mellitus
    Product
    albiglutide, exenatide, liraglutide
    Collaborators
    Not applicable
    Study date(s)
    October 2014 to December 2029
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    Not applicable
    Accepts healthy volunteers
    none
    • A record of medullary thyroid carcinoma (MTC) identified from the US state/regional population-based cancer registries
    • N/A
    Inclusion and exclusion criteria
    Inclusion criteria:
    • A record of medullary thyroid carcinoma (MTC) identified from the US state/regional population-based cancer registries
    Exclusion criteria:
    • N/A

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Protocol
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    No study documents available

    Recruitment status
    Recruitment complete
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website